Abstract
Almost 20-40% of all patients suffering from diabetes mellitus experience chronic kidney disease, which is related to higher mortality (cardiovascular and all-cause). The implication of several pathophysiological mechanisms (hemodynamic, tubular, metabolic and inflammatory) in the pathogenesis of diabetic kidney disease generates an urgent need to develop multitarget therapeutic strategies to face its development and progression. SGLT2 inhibitors are undoubtedly a practice-changing drug class for individuals who experience type 2 diabetes and diabetic kidney disease. In vitro studies, exploratory research, sub-analyses of large randomized controlled trials, and investigation of several biomarkers have demonstrated that SGLT2 inhibitors achieved multiple beneficial activities, targeting several renal cellular and molecular pathways independent of their antihyperglycemic activity. These mainly include the reduction in intraglomerular pressure through the restoration of TGF, impacts on the renin-angiotensin-aldosterone system, improvement of renal hypoxia, adaptive metabolic alterations in substrate use/energy expenditure, improvement of mitochondrial dysfunction, and reduction of inflammation, oxidative stress and fibrosis. This manuscript thoroughly investigates the possible mechanisms that underlie their salutary renal effects in patients with diabetes, focusing on several pathways involved and the interplay between them. It also explores their upcoming role in ameliorating the evolution of chronic kidney disease in patients with diabetes.
Keywords: Type 2 diabetes, SGLT2 inhibitors, Glucosuria, Albuminuria, Chronic kidney disease, TGF.
Current Molecular Pharmacology
Title:SGLT2 Inhibitors and Diabetic Kidney Disease: Targeting Multiple and Interrelated Signaling Pathways for Renal Protection
Volume: 17
Author(s): Georgios S. Papaetis*
Affiliation:
- K.M.P THERAPIS Paphos Medical Center, Internal Medicine and Diabetes Clinic, 14 Vasileos Georgiou B Street, Office 201, 8010, Paphos, Cyprus
- CDA College, 73 Democratias Avenue, Paphos, Cyprus
Keywords: Type 2 diabetes, SGLT2 inhibitors, Glucosuria, Albuminuria, Chronic kidney disease, TGF.
Abstract: Almost 20-40% of all patients suffering from diabetes mellitus experience chronic kidney disease, which is related to higher mortality (cardiovascular and all-cause). The implication of several pathophysiological mechanisms (hemodynamic, tubular, metabolic and inflammatory) in the pathogenesis of diabetic kidney disease generates an urgent need to develop multitarget therapeutic strategies to face its development and progression. SGLT2 inhibitors are undoubtedly a practice-changing drug class for individuals who experience type 2 diabetes and diabetic kidney disease. In vitro studies, exploratory research, sub-analyses of large randomized controlled trials, and investigation of several biomarkers have demonstrated that SGLT2 inhibitors achieved multiple beneficial activities, targeting several renal cellular and molecular pathways independent of their antihyperglycemic activity. These mainly include the reduction in intraglomerular pressure through the restoration of TGF, impacts on the renin-angiotensin-aldosterone system, improvement of renal hypoxia, adaptive metabolic alterations in substrate use/energy expenditure, improvement of mitochondrial dysfunction, and reduction of inflammation, oxidative stress and fibrosis. This manuscript thoroughly investigates the possible mechanisms that underlie their salutary renal effects in patients with diabetes, focusing on several pathways involved and the interplay between them. It also explores their upcoming role in ameliorating the evolution of chronic kidney disease in patients with diabetes.
Export Options
About this article
Cite this article as:
Papaetis S. Georgios*, SGLT2 Inhibitors and Diabetic Kidney Disease: Targeting Multiple and Interrelated Signaling Pathways for Renal Protection, Current Molecular Pharmacology 2024; 17 : e18761429261105 . https://dx.doi.org/10.2174/0118761429261105231011101200
DOI https://dx.doi.org/10.2174/0118761429261105231011101200 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
Call for Papers in Thematic Issues
Advances in the Diagnosis and Treatment of Head and Neck Disease
Head and neck diseases encompass a wide range of conditions affecting the oral cavity, pharynx, larynx, nasal passages, sinuses, salivary glands, and other structures of the head and neck region. These diseases can have significantly on essential function, such as breathing, swallowing, speaking, as well as the quality of life. ...read more
New Cell Death Regulation Drugs for Cardiovascular Diseases
Cardiovascular diseases are the leading cause of mortality worldwide, with aberrant cell death processes playing a crucial role in their pathogenesis. Cell death in these diseases encompasses not only well-studied forms of apoptosis but also includes a variety of complex modes such as mitochondrial permeability transition (MPT)-driven necrosis, entotic cell ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters Immunotherapy and Targeted Therapy Combinations in Renal Cancer
Current Clinical Pharmacology DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews Dyslipidemia, Metabolic Syndrome and Vascular Disease Among Asian Indians
Vascular Disease Prevention (Discontinued) Acute Physical Stress Increases Serum Levels of Specific microRNAs
MicroRNA Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines
Mini-Reviews in Medicinal Chemistry Polyunsaturated Fatty Acids and Inflammation: Therapeutic Potential in Rheumatoid Arthritis
Current Rheumatology Reviews Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials Capturing and Amplifying Impurities from Recombinant Therapeutic Proteins Via Combinatorial Peptide Libraries: A Proteomic Approach
Current Pharmaceutical Biotechnology B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Impact of Omega-3 Fatty Acids on Osteoporosis
Current Pharmaceutical Design Cerebrospinal Fluid Inflammatory Markers in Alzheimer’s Disease: Influence of Comorbidities
Current Alzheimer Research Design, Synthesis, Pharmacological Evaluation and Descriptor Based Similarities Study of N,N-diphenyl-2-[4-(substituted phenyl)piperazin-1- yl]acetamides as Potential Antipsychotics
Medicinal Chemistry Recent Advances in Bone Graft Technologies
Recent Patents on Biomedical Engineering (Discontinued) Two Panels of Steroid Receptor Luciferase Reporter Cell Lines for Compound Profiling
Combinatorial Chemistry & High Throughput Screening Synthesis and Cytotoxic Evaluation of Novel Symmetrical Taspine Derivatives as Anticancer Agents
Medicinal Chemistry Bacterial Translocation, Microcirculation Injury and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
Current Medicinal Chemistry Effects of Subhypothermia on Ca2+, Mg2+, Excitatory Amino Acids and Plasma Endothelin in Brain Tissues of Mice with Acute Cerebral Infarction
Vascular Disease Prevention (Discontinued)